Immunglobulınler ve Myastenia Gravıs: Geleneksel Derleme

Authors : Hilal Kaya, Zekai Halıcı

Pages : 280-286

Doi:10.17827/aktd.1559702

View : 5 | Download : 4

Publication Date : 2024-12-31

Article Type : Review Paper

Abstract :Myasthenia Gravis is an autoimmune disease characterised by the development of antibodies against proteins in the neuromuscular junction, resulting in complaints such as fatigue and muscle weakness. Quality of life is adversely affected due to complaints such as droopy eyelids (ptosis), blurred or double vision, difficulty in speaking, difficulty in swallowing and breathing. It causes morbidity and mortality due to myasthenic crisis and subsequent complications. Intravenous immunoglobulin therapy, plasmapheresis, anticholinesterase drugs, immunosuppressant drugs or thymectomy surgery can be applied in the treatment of myasthenia gravis, which can lead to serious permanent damage and rarely fatal consequences. Treatment preference varies according to the course of the disease. In this review, pharmacokinetics, administration procedures, adverse events, patient variables and cost considerations of intravenous immunoglobulin (IVIg) in myasthenia gravis will be discussed.
Keywords : İntravenöz İmmunglobulin, IVIg, Myastenia Gravis